2009APA急性應激障礙和創(chuàng)傷后應激障礙治療指南
《2009APA急性應激障礙和創(chuàng)傷后應激障礙治療指南》內(nèi)容簡介：
In a 2006 Cochrane meta-**ysis, Stein et al. （4） re-viewed 35 short-term randomized controlled trials （of14 or fewer weeks in duration） involving a total of 4,597participants. In 17 of the trials, symptom severity was sig-nificantly reduced in the medication groups relative toplacebo. Evidence of efficacy was most convincing for theSSRIs, across all symptom clusters and for co-occurringdepression and disability.
《2009APA急性應激障礙和創(chuàng)傷后應激障礙治療指南》內(nèi)容預覽：
In a 2006 re**ysis of two previously published trials,Stein et al. （6） examined 395 ** patients with PTSD whowere randomized to double-blind treatment with flexiblydosed sertraline （50–200 mg/day） or placebo. After 12weeks, sertraline was significantly more effective than pla-cebo on most primary efficacy variables including Part 2 ofthe CAPS, irrespective of whether the patients had expe-rienced childhood abuse or interpersonal trauma, suggest-ing the utility of medication treatment in individualswhose precipitating trauma is either childhood abuse inparticular or interpersonal trauma in general.
In a 2005 study, Davidson et al. （7） compared the relapserates of 57 of 62 total patients who responded to 6 monthsof open-label fluoxetine and who were subsequently blindlyrandomized to continue receiving fluoxetine （mean dosage =42.1 mg/day） or placebo. Relapse rates were 22% for flu-oxetine compared with 50% for placebo （p=0.02）； the oddsratio for relapse on placebo relative to fluoxetine was 3.50,and time to relapse on fluoxetine was longer than on pla-cebo （p = 0.02, log rank statistic）。
點擊下載***：《2009APA急性應激障礙和創(chuàng)傷后應激障礙治療指南》
本站所注明來源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉(zhuǎn)載的媒體或個人可與我們
聯(lián)系zlzs@120.net，我們將立即進行刪除處理
熱點圖文
-
談話療法或有效降低**率
一項大規(guī)模研究發(fā)現(xiàn)，對**高風險人群采取談話療法，可明顯降低他們的**率。...[詳細]
-
2004VADoD創(chuàng)傷后應激障礙管理臨床實踐指南
The goal of this Guideline project wa...[詳細]
